NovaBay Pharmaceuticals to Hold Third Quarter 2018 Conference Call on November 14, 2018
November 07 2018 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company focusing on commercializing prescription
Avenova® for the domestic eye care market, announces that it will
report third quarter 2018 financial results after market close on
Wednesday, November 14. Management will hold an investment
community conference call that day to discuss financial results and
provide a Company update.
DATE: Wednesday, November 14 TIME: 4:30
p.m. ET / 1:30 p.m. PT DIAL IN: 800-608-8202 from within the U.S.
702-495-1913 from outside the U.S. Enter conference identification
number 5709629
The live call also will be available at
http://novabay.com/investors/events. A replay of the call will be
available beginning two hours after its completion through 11:59
p.m. Eastern time November 20, 2018, by dialing 855-859-2056 from
within the U.S. or 404-537-3406 from outside the U.S. and entering
the conference identification number 5709620. The call will also be
archived at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focused on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for the wound care
market and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in dermatology and urology.
Socialize and Stay informed on NovaBay’s progress:Like
us on FacebookFollow us on TwitterConnect
with NovaBay on LinkedInJoin us
on Google+Visit NovaBay’s Website
NovaBay ContactsFor NovaBay Avenova purchasing
information:Please Call us toll free: 1-800-890-0329 or
email sales@avenova.com.www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181107005325/en/
NovaBay Pharmaceuticals, Inc.Jack McGovern,
510-899-8800Chief Executive Officer andChief Financial
Officerjmcgovern@novabay.comorInvestor ContactLHA Investor
RelationsJody Cain, 310-691-7100jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024